Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.

Kazuki AbeKaito ShibataTakafumi NaitoAtsushi OtsukaMasato KarayamaMasato MaekawaHideaki MiyakeTakafumi SudaJunichi Kawakami

Published in: European journal of clinical pharmacology (2021)

Cachexia progression had a negative impact on serum nivolumab in cancer patients. The interindividual variation in serum nivolumab was characterized by cachexia progression in addition to blood components.

Keyphrases

peripheral blood